Search Results - "Hammond, Sarah P"
-
1
-
2
The Novel Coronavirus Disease (COVID-19) Threat for Patients With Cardiovascular Disease and Cancer
Published in JACC CardioOncology (01-06-2020)Get full text
Journal Article -
3
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Published in Blood cancer journal (New York) (01-08-2023)“…Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to…”
Get full text
Journal Article -
4
Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation
Published in Blood advances (28-08-2018)“…Patients treated with allogeneic hematopoietic cell transplantation (HCT) are at risk of cytomegalovirus (CMV) reactivation and disease, which results in…”
Get full text
Journal Article -
5
Molecular Methods To Improve Diagnosis and Identification of Mucormycosis
Published in Journal of Clinical Microbiology (01-06-2011)“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text
Journal Article -
6
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
Published in Journal of fungi (Basel) (10-12-2021)“…The use of targeted biologic therapies for hematological malignancies has greatly expanded in recent years. These agents act upon specific molecular pathways…”
Get full text
Journal Article -
7
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease
Published in Journal of antimicrobial chemotherapy (01-12-2017)“…A two-part (Phase 1B/3), sequential, open-label, multicentre study evaluated the pharmacokinetics (PK) and safety of intravenous (iv) posaconazole given as…”
Get full text
Journal Article -
8
Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation
Published in Clinical infectious diseases (16-08-2019)“…Abstract There were no cases of tuberculosis in a cohort of 2531 patients who underwent hematopoietic cell transplantation from 2010 to 2015 after 7323…”
Get full text
Journal Article -
9
Isavuconazole Treatment of a Patient with Disseminated Mucormycosis
Published in Journal of Clinical Microbiology (01-03-2014)“…Classifications Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
10
Mortality in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients with Mucormycosis, 2001 to 2009
Published in Antimicrobial Agents and Chemotherapy (01-11-2011)“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
11
Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation
Published in Clinical infectious diseases (01-08-2017)“…Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that…”
Get full text
Journal Article -
12
Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors
Published in Breast cancer research and treatment (01-11-2015)“…Opportunistic infection with Pneumocystis jiroveci pneumonia (PCP) has not been recognized as a significant complication of early-stage breast cancer…”
Get full text
Journal Article -
13
Respiratory Virus Detection in Immunocompromised Patients with FilmArray Respiratory Panel Compared to Conventional Methods
Published in Journal of Clinical Microbiology (01-10-2012)“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text
Journal Article -
14
Cytomegalovirus events in high‐risk allogeneic hematopoietic‐cell transplantation patients who received letermovir prophylaxis
Published in Transplant infectious disease (01-08-2021)“…Letermovir is approved for the prevention of cytomegalovirus (CMV) reactivation and clinical disease in patients undergoing allogeneic hematopoietic‐cell…”
Get full text
Journal Article -
15
Infections in Composite Tissue Allograft Recipients
Published in Infectious disease clinics of North America (01-06-2013)“…This article summarizes infectious complications in recipients of facial and hand composite tissue allotransplantation (CTA) and reviews infection prophylaxis…”
Get full text
Journal Article -
16
Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
Published in Pilot and feasibility studies (16-06-2023)“…Multiple vaccines have been approved since August 2021 to prevent infection with SARS-CoV-2; however, 20-40% of immunocompromised people fail to develop…”
Get full text
Journal Article -
17
Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience
Published in Open forum infectious diseases (01-09-2015)“…Invasive fusariosis is an aggressive fungal disease among immunocompromised patients. Mortality remains high in the voriconazole era. Combination therapy…”
Get full text
Journal Article -
18
The Clinical Significance of Cytomegalovirus Viremia after Chimeric Antigen Receptor T-Cell Therapy
Published in Clinical infectious diseases (01-03-2024)Get full text
Journal Article -
19
Defining infection risk of bispecific antibodies for myeloma
Published in Blood advances (24-09-2024)Get full text
Journal Article -
20
Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies
Published in Transplant infectious disease (01-11-2023)“…Background Chimeric antigen receptor (CAR)‐T‐cell therapies have revolutionized the management of acute lymphoblastic leukemia, non‐Hodgkin lymphoma, and…”
Get full text
Journal Article